Rare carcinoma of pancreas

Rare carcinoma of the pancreas (Orphanet code 217074) is a grouping term that encompasses uncommon malignant epithelial tumors arising in the pancreas that fall outside the much more common pancreatic ductal adenocarcinoma. This category includes several distinct histological subtypes such as acinar cell carcinoma, pancreatoblastoma, medullary carcinoma, hepatoid carcinoma, signet ring cell carcinoma, undifferentiated carcinoma, and other exceptionally rare variants. These tumors primarily affect the pancreas but can spread to surrounding structures including the liver, peritoneum, lymph nodes, and lungs. Symptoms often overlap with those of typical pancreatic cancer and may include abdominal or back pain, unintentional weight loss, jaundice (yellowing of the skin and eyes), nausea, loss of appetite, and new-onset diabetes. Some subtypes, such as acinar cell carcinoma, may present with unique features like lipase hypersecretion syndrome, which causes subcutaneous fat necrosis and polyarthralgia. Because these tumors are rare, there is limited high-quality evidence to guide treatment, and management is often extrapolated from experience with pancreatic ductal adenocarcinoma or based on case series. Surgical resection remains the primary curative approach when the tumor is localized and resectable. Chemotherapy regimens, including gemcitabine-based or platinum-based protocols, may be used in the adjuvant or palliative setting depending on the specific histological subtype and stage at diagnosis. Some subtypes, such as pancreatoblastoma, may respond better to chemotherapy than conventional ductal adenocarcinoma. Prognosis varies considerably by subtype; certain rare variants may carry a somewhat better prognosis than typical pancreatic ductal adenocarcinoma, while undifferentiated forms tend to be highly aggressive. Multidisciplinary care involving oncologists, surgeons, gastroenterologists, and pathologists is essential for accurate diagnosis and optimal management.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Rare carcinoma of pancreas